GENB
OtherGenerate Biomedicines Inc
Live · NASDAQ · May 9, Close
What's Moving GENB Today?
No stock-specific AI insight has been generated for GENB yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
GENB News
6 articles- Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 7, 2026
- H.C. Wainwright Initiates Coverage of Generate Biomedicines (GENB) With a Buy RatingYahoo Finance·Apr 20, 2026
- Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsightGlobeNewswire Inc.·Apr 7, 2026
- Generate Biomedicines (GENB) Valuation Check After Recent Share Price WeaknessYahoo Finance·Mar 8, 2026
- Sector Update: Health Care Stocks Advance Late AfternoonYahoo Finance·Feb 27, 2026
- Generate Biomedicines, Inc. Announces Pricing of Initial Public OfferingYahoo Finance·Feb 27, 2026
All 6 articles loaded
Price Data
Fundamentals
Trading
About Generate Biomedicines Inc
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.